INSIDE CAMBRIDGE-1

Get the first look at the UK’s most powerful AI supercomputer.

INSIDE CAMBRIDGE-1

Explore the computational instrument for AI healthcare, featuring 80 NVIDIA DGX A100 systems.

INSIDE CAMBRIDGE-1

Powered by 100% renewable energy, the supercomputer will tackle the most challenging AI training, inference, and data science workloads at scale.

INSIDE CAMBRIDGE-1

Top UK companies, universities, and startups will use the supercomputer to solve healthcare’s greatest challenges, from genomics to drug discovery.

Unveiling Cambridge-1: The UK’s Most Powerful AI Supercomputer

On Wednesday, July 7, 2021 at 2PM BST (6AM PDT) watch leading research institutions reveal their groundbreaking research to be conducted on Cambridge-1 that will propel healthcare forward.

Designed to Solve the Most Pressing
Medical Challenges with AI

NVIDIA’s first supercomputer for external research access, Cambridge-1 will enable the UK healthcare ecosystem to tap into massively powerful computing resources to fully harness the capabilities of AI.

Cambridge-1 will be powered by 80 NVIDIA DGX™ A100 systems and connected with NVIDIA® Mellanox® InfiniBand networking, delivering 400 petaflops of AI compute and 8 petaflops of LINPACK performance. Powered by completely renewable energy, it’s expected to rank among world’s top 5 green supercomputers.

Supercharging Healthcare Research with UK’s Leaders

Top pharmaceutical companies, tech startups, and members of academia and research plan to use Cambridge-1 for a variety of projects that will greatly expand the boundaries of science—improving patient care, identifying causes of diseases, and tailoring targeted therapeutics for patients.

GSK

“AI and machine learning are like a new microscope that will help scientists to see things that they couldn’t see otherwise. NVIDIA’s investment in computing, combined with the power of deep learning, will enable solutions to some of the life sciences industry’s greatest challenges and help us continue to deliver transformational medicines and vaccines to patients. Together with GSK’s new AI lab in London, I am delighted that these advanced technologies will now be available to help the UK’s outstanding scientists.”

— Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK

“The use of big data, supercomputing, and artificial intelligence have the potential to transform research and development, from target identification through clinical research and all the way to the launch of new medicines.”

— James Weatherall, PhD, Head of Data Science and AI, AstraZeneca

AstraZeneca
King’s College London

“Recent advances in AI have seen increasingly powerful models being used for complex tasks such as image recognition and natural language understanding. These models have achieved previously unimaginable performance by using an unprecedented scale of computational power, amassing millions of GPU hours per model. Through this partnership, for the first time, such a scale of computational power will be available to healthcare research—it will be truly transformational for patient health and treatment pathways.”

— Sebastien Ourselin, Head of the School of Biomedical Engineering and Imaging Sciences, King's College London

“If AI is to be deployed at scale for patient care, then accuracy, robustness, and safety are of paramount importance. We need to ensure AI researchers have access to the largest and most comprehensive datasets that the NHS has to offer, our clinical expertise, and the required computational infrastructure to make sense of the data. This approach is not only necessary but also the only ethical way to deliver AI in healthcare—more advanced AI means better care for our patients.”

— Dr. Ian Abbs, Chief Executive and Chief Medical Officer, Guy’s and St Thomas’ NHS Foundation Trust

Guy’s and St Thomas’ NHS Foundation Trust
 Oxford Nanopore Technologies

“Compact AI has enabled real-time sequencing in the palm of your hand, and AI supercomputers are enabling new scientific discoveries in large-scale genomic datasets. These complementary innovations in data analysis support a wealth of impactful science in the UK and, critically, support our goal of bringing genomic analysis to anyone, anywhere.”

— Gordon Sanghera, CEO, Oxford Nanopore Technologies

“[The announcement from NVIDIA] is an exciting moment for the UK’s world-leading healthcare industry and a tremendous vote of confidence in the UK as an international centre for research, AI, and innovation. Accelerating drug discovery has never been so important, and it is investments like this that can make a real difference in our fight against countless diseases. I care about technology because I care about people and NVIDIA’s new supercomputer will aid the UK’s best and brightest to undertake research that will save lives.”

— Matt Hancock, Secretary of State for Health and Social Care, UK

Cambridge-1 News

Follow us on Twitter for the latest news.

Hear from NVIDIA’s Marc Hamilton on constructing Cambridge-1

Building During a Pandemic

Hear from NVIDIA’s Marc Hamilton on constructing Cambridge-1 during a pandemic.

NVIDIA is building the UK’s most powerful supercomputer

Announcing Cambridge-1

Learn how NVIDIA is building the UK’s most powerful supercomputer.

Sign up for the latest NVIDIA healthcare news, including updates on Cambridge-1.